Header Image: Zoë Biehl/Psymposia

During unstable times like we are facing with the Covid-19 pandemic, the demand for mental health naturally rises. With the increasing interest in the healing benefits of psychedelic therapies, it makes sense that the demand for these methods are also spiking right now. But because of social distancing, isolation, and full on quarantines, most are not willing to leave the house – even for their favorite forms of therapy.

New York Based Company MindBloom is now offering remote-enabled psychedelic therapy to patients in the state of New York. They are hoping to also expand their reach to add additional states in the next 30 days.

Earlier this month, the DEA lifted sanctions requiring in-person visits for the prescribing of controlled substances as long as medical providers communicate using audio and visual elements. Meaning that doctors can now offer the ketamine needed for the therapies remotely.

Clients receive personalized, remotely-facilitated psychedelic therapy programs and ongoing virtual support from licensed psychiatric clinicians. From initial video consultations to post-treatment 1:1 virtual integration therapy and coaching, Mindbloom clients will be supported and supervised every step of the way.

What does this psychedelic therapy consist of?

Following an online survey to assess qualifying symptoms such as anxiety and depression, new clients consult with a licensed psychiatric clinician over video.

Ketamine tablets are prescribed and delivered to qualifying clients’ homes.

The first therapy session is scheduled; each session requires an in-person peer monitor to be present for the duration of the session.

A virtual provider prepares the client and peer monitor ahead of the session and remains available on-demand throughout the session.

Audioscapes and personalized psychedelic therapy content is available through Mindbloom’s web-based online platform to enhance the at-home experience.

Following each session, virtual providers are available to provide 1:1 integration therapy.

Read the full press release from MindBloom Here:

MINDBLOOM OFFERS REMOTE-ENABLED PSYCHEDELIC THERAPY TO

HOMEBOUND NEW YORKERS

Federal administration greenlights expanded telehealth services to reduce COVID-19 exposure; Demand for psychedelic medicine spikes during public mental health crisis.

NEW YORK, NY., March 20, 2020 – Mindbloom, a New York City-based mental health and wellbeing company facilitating guided psychedelic therapy for anxiety and depression, has announced remote treatment options in response to the escalating coronavirus pandemic. The company now offers medically supervised virtual ketamine therapy sessions to both new and existing clients in the state of New York, with plans to add services to additional states within 30 days.

In light of federal mandates for Americans to practice social distancing and limit exposure, Mindbloom is lifting its requirement for new clients to begin their journey with an in-person visit at their Manhattan center. Now, clients can embark on a guided psychedelic therapy program from the comfort and safety of their own home through a virtually-assisted session. The company’s NoMad space will re-open when it is safe to resume in-person services.

Said Mindbloom Medical Director Dr. Casey Paleos, “As the COVID-19 pandemic escalates in the U.S. and state of New York, conditions for anxiety and depression have never been higher. Our clinicians feel called to service in this time of crisis, and our team has worked tirelessly to keep psychedelic medicine accessible and affordable for the people who need it most.” He added, “We are evolving Mindbloom’s telehealth approach in real-time to best serve our existing clients and respond to the overwhelming demand we have experienced from new clients since the coronavirus outbreak.”

Earlier this month, the DEA lifted sanctions requiring in-person visits for the prescribing of controlled substances as long as medical providers communicate using audio and visual elements. Many states are also lifting in-state licensure requirements, allowing clinicians to practice via telemedicine in any state. The American Telemedicine Association is calling on more state governors to lift this requirement in order to increase access to care. These federal and state government responses have enabled Mindbloom’s fully remote protocols and national expansion.

Founder and CEO Dylan Beynon explained, “Virtual visits have always been a cornerstone of our model. Mindbloom began piloting these protocols several months prior to the onset of COVID-19, and we’ve safely and successfully facilitated over 200 remote sessions with overwhelmingly positive client outcomes and feedback.” He added, “We are fortunate to be in the position to accelerate the roll-out of our remote ketamine therapy programs in response to one of the greatest public health challenges Americans have ever faced.”

Using Mindbloom’s software platform, clients receive personalized, remotely-facilitated psychedelic therapy programs and ongoing virtual support from licensed psychiatric clinicians. From initial video consultations to post-treatment 1:1 virtual integration therapy and coaching, Mindbloom clients will be supported and supervised every step of the way.

How It Works:

Following an online survey to assess qualifying symptoms such as anxiety and depression, new clients consult with a licensed psychiatric clinician over video.

Ketamine tablets are prescribed and delivered to qualifying clients’ homes.

The first therapy session is scheduled; each session requires an in-person peer monitor to be present for the duration of the session.

A virtual provider prepares the client and peer monitor ahead of the session and remains available on-demand throughout the session.

Audioscapes and personalized psychedelic therapy content is available through Mindbloom’s web-based online platform to enhance the at-home experience.

Following each session, virtual providers are available to provide 1:1 integration therapy.

Mindbloom was established to increase Americans’ access to affordable and effective science-backed therapeutic experiences designed by leaders in the fields of psychiatry and psychedelic medicine. Founded by seasoned tech entrepreneur Dylan Beynon and clinically overseen by one of America’s foremost psychedelic medicine experts, Dr. Casey Paleos, Mindbloom’s initial offering is guided ketamine therapy, affordably priced at $150 – $250 per session.

For more information about Mindbloom’s remote treatment options, safety precautions, or how to request a new client consultation, visit www.mindbloom.co

About Mindbloom, Inc.

Mindbloom is America’s leading destination for cutting-edge, science-backed approaches to achieving and maintaining optimal mental health and wellbeing through psychedelic medicine. Founded in New York City by seasoned tech entrepreneur Dylan Beynon, Mindbloom brings clinicians, researchers and technologists together to deliver guided ketamine therapy in a supportive, thoughtfully designed, hospitality-inspired environment. Treatment protocols are overseen by Medical Director and board certified psychiatrist Dr. Casey Paleos, a pioneer in psychedelic research and treatment, and artfully crafted to help clients grow, heal and expand their human potential through a deeper therapeutic experience.

Press Inquiries:

Trailblaze on behalf of Mindbloom

hello@trailblaze.co